•• Complete epithelial recovery was achieved by 67% of subjects receiving NEXAGON, as opposed to 27% receiving Vehicle alone
•• NEXAGON was well-tolerated demonstrating a safety profile similar to vehicle
•• Amber plans to initiate the NEXPEDE-1 Phase 2/3 clinical trial in subjects with PCED of various etiologies in Q1 2023 ••

With the addition of a cornea specialist, patients will have increased access to specialty vision care, improving overall healthcare outcomes for the community

In September, Dr. Nauheim was named to the Consumers' Research Council of America "Guide to America's Top Ophthalmologists" for the third consecutive year.

International Stem Cell Corporation announced that the United States Patent and Trademark Office has granted ISCO a patent relating to the company's development of human non-embryonic parthenogenetic stem cells. Human parthenogenetic stem cells are